Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Lung cancer is one of the most lethal diseases worldwide, and the survival rate is less than 15% even after the treatment. Unfortunately, chemotherapeutic treatments for lung cancer are accompanied by severe side effects, lack of selectivity and multidrug resistance. In order to overcome the limitations of conventional chemotherapy, nanoparticle-mediated RNA interference drugs represent a potential new approach due to selective silencing effect of oncogenes and multidrug resistance related genes. In this review, we provide recent advancements on nanoparticle-mediated siRNA delivery strategies including lipid system, polymeric system and rigid nanoparticles for lung cancer therapies. Importantly, codelivery of siRNA with conventional anticancer drugs and recent theranostic agents that offer great potential for lung cancer therapy is covered.
Department of Molecular Genetics, School of Dentistry, Seoul National University, Seoul 110-749, Republic of Korea.
Young-Dong
YD
Kim
Tae-Eun
TE
Park
Bijay
B
Singh
Sushila
S
Maharjan
Yun-Jaie
YJ
Choi
Pill-Hoon
PH
Choung
Rohidas B
RB
Arote
Chong-Su
CS
Cho
D000818:Animals; D006801:Humans; D008055:Lipids / Q000737:chemistry; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D053758:Nanoparticles / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000627:therapeutic use*; D000067492:RNAi Therapeutics / Q000379:methods*
D008055:Lipids; D011108:Polymers; D034741:RNA, Small Interfering
RNA interference; codelivery system; lung cancer; nanoparticle; siRNA delivery system